General Federal Contracts — March 25, 2026

$927M obligated to Elevance and Emergent through 2027+ with $515M outlayed, plus $263M to nonprofits, underscores steady cash flow in CMS/ASPR programs.

$205M firm obligations to ElbitAmerica (DHS surveillance) and Pyramid (GSA/HUD IT) start 2026 with options/extensions to 2030/2026, no outlays yet but fully funded base.

$2.95B Caltech JPL operations (68% total value) with $2.43B outlayed through 2028 reflects NASA's FFRDC reliance but no direct equity plays.

Long tenors (2026-2030) across 6/7 contracts expose to funding cuts/delays; $0 outlay on Elbit/Pyramid delays revenue.

Firm-fixed-price terms (Emergent $422M, Elbit $105M) risk cost overruns; award-fee/no-fee limits profits (Elevance, Mount Sinai).

Foreign-owned entities (Emergent Canada, ElbitAmerica) in HHS/DHS face scrutiny; 20%+ subawards (Elevance $171M, RTI $23M) add dependency.

Unexercised options total ~$350M+ (Caltech $202M, Emergent $284M, Mount Sinai $44M, Elbit/Pyramid minor).

Remaining outlays ~$1.3B ($518M Caltech, $246M Elevance, $167M Emergent, $54M RTI).

Small biz set-asides like Pyramid $100M position for GSA/HUD follow-ons.

$1.19B (28%) across IT, pharma, R&D signals CMS/ASPR/NIH prioritization.

Caltech's $2.95B (68%) locks in JPL ops to 2028.

$205M new-ish awards for DHS surveillance/HUD IT start 2026.

{"entity"=>"Emergent BioSolutions", "reason"=>"$422M obligated with $284M options to 2029 in biopharma preparedness.", "trigger"=>"option exercises or outlay >$300M"}

{"entity"=>"ElbitAmerica (Elbit Systems)", "reason"=>"$105M DHS surveillance from 2026 with foreign-ownership risks.", "trigger"=>"first outlays or extension to 2030"}

{"entity"=>"Pyramid Systems", "reason"=>"$100M small biz IT BPA with near-term 2026 end.", "trigger"=>"extension to Sep 2026 or new GSA calls"}

{"entity"=>"Elevance Health (National Govt Services)", "reason"=>"$505M CMS IT steady outlays through 2027.", "trigger"=>"subaward flow or award fee adjustments"}